EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand

BACKGROUND: The randomized phase II INTELLANCE-2/EORTC_1410 trial on EGFR-amplified recurrent glioblastomas showed a trend towards improved overall survival when patients were treated with depatux-m plus temozolomide compared with the control arm of alkylating chemotherapy only. We here performed tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoogstrate, Youri, Vallentgoed, Wies, Kros, Johan M, de Heer, Iris, de Wit, Maurice, Eoli, Marica, Sepulveda, Juan Manuel, Walenkamp, Annemiek M E, Frenel, Jean-Sebastien, Franceschi, Enrico, Clement, Paul M, Weller, Micheal, van Royen, Martin E, Ansell, Peter, Looman, Jim, Bain, Earle, Morfouace, Marie, Gorlia, Thierry, Golfinopoulos, Vassilis, van den Bent, Martin, French, Pim J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212878/
https://www.ncbi.nlm.nih.gov/pubmed/32642719
http://dx.doi.org/10.1093/noajnl/vdz051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212878/
https://www.ncbi.nlm.nih.gov/pubmed/32642719
http://dx.doi.org/10.1093/noajnl/vdz051

Ejemplares similares